Last quarter (Q3 2022), Astellas Pharma's total revenue was ¥402.18B, an increase of 18.07% from the same quarter last year. In Q3, Astellas Pharma's net income was ¥48.41B. See Astellas Pharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19
Total Revenue	¥ 1.09T	-	¥ 1.30T	¥ 1.25T	¥ 1.30T	¥ 1.31T
Cost of Revenue	¥ 222.21B	-	¥ 253.01B	¥ 246.06B	¥ 276.74B	¥ 292.05B
Gross Profit	¥ 865.63B	-	¥ 1.04T	¥ 1.00T	¥ 1.02T	¥ 1.01T
Operating Expense	¥ 783.49B	-	¥ 912.19B	¥ 867.89B	¥ 778.45B	¥ 768.76B
Operating Income	¥ 82.14B	-	¥ 130.96B	¥ 135.57B	¥ 245.65B	¥ 245.54B
Net Non Operating Interest Income Expense	¥ 69.00M	-	¥ 1.20B	¥ 9.27B	¥ 1.36B	¥ 5.06B
Other Income Expense	-	-	-	-	-	-
Pretax Income	¥ 80.92B	-	¥ 156.89B	¥ 145.32B	¥ 245.35B	¥ 248.97B
Tax Provision	¥ 16.11B	-	¥ 32.80B	¥ 24.73B	¥ 49.94B	¥ 26.70B
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	¥ 64.81B	-	¥ 124.09B	¥ 120.59B	¥ 195.41B	¥ 222.26B
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	¥ 1.01T	-	¥ 1.17T	¥ 1.11T	¥ 1.06T	¥ 1.06T
Net Income From Continuing And Discontinued Operation	¥ 64.81B	-	¥ 124.09B	¥ 120.59B	¥ 195.41B	¥ 222.26B
Normalized Income	¥ 64.56B	-	¥ 104.92B	¥ 120.59B	¥ 195.41B	¥ 222.26B
Interest Expense	¥ 5.87B	-	¥ 4.95B	¥ 2.33B	¥ 3.00B	¥ 1.30B
EBIT	¥ 86.80B	-	¥ 161.84B	¥ 147.66B	¥ 248.35B	¥ 250.27B
EBITDA	¥ 167.75B	¥ 246.88B	¥ 241.52B	¥ 220.31B	¥ 314.75B	¥ 313.73B

Currency in JPY

Astellas Pharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing